Patients living with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for HCV

Viral Infections, Non-HIV

Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease

Hepatology.

Backus LI, Belperio PS, Shahoumian TA, Mole LA

doi: 10.1002/hep.29811.

HIV / AIDS

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)

Sci Rep.

Dold L, Schwarze-Zander C, Boesecke C, Mohr R, Langhans B, Wasmuth JC, Strassburg CP, Rockstroh JK, Spengler U

doi: 10.1038/s41598-019-48756-3.

HIV / AIDS

Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies

J Hepatol.

Wandeler G, Mauron E, Atkinson A, Dufour JF, Kraus D, Reiss P, Peters L, Dabis F, Fehr J, Bernasconi E, van der Valk M, Smit C, Gjærde LK, Rockstroh J, Neau D, Bonnet F, Rauch A, Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort

doi: 10.1016/j.jhep.2019.03.032.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

Hepatology.

Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S

doi: 10.1002/hep.29642.

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

HIV / AIDS

Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA

HIV Med.

Mills AM, Schulman KL, Fusco JS, Brunet L, Hsu R, Beyer A, Prajapati G, Mounzer K, Fusco GP

doi: 10.1111/hiv.12826.

SPECIAL REPORT

HIV / AIDS

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021

Viral Infections, Non-HIV

Interest of variations in miR-152 and miR-122 in a series of hepatocellular carcinomas related to HCV infection

Hepatol Res.

Miquelestorena-Standley E, Tallet A, Collin C, Piver E4, De Muret A, Salamé E, Bourlier P, Kervarrec T, Guyétant S, Pagès JC

doi: 10.1111/hepr.12915.

HIV / AIDS

Immune deficiency is a risk factor for severe COVID-19 in people living with HIV

HIV Med

Hoffmann C, Casado JL, Härter G, Vizcarra P, Moreno A, Cattaneo D, Meraviglia P, Spinner CD, Schabaz F, Grunwald S, Gervasoni C

doi: 10.1111/hiv.13037

Related content

Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)

Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA

11e Conférence de la Société internationale sur le SIDA (IAS) 2021

Interest of variations in miR-152 and miR-122 in a series of hepatocellular carcinomas related to HCV infection

Immune deficiency is a risk factor for severe COVID-19 in people living with HIV

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021